| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Future Medicinal Chemistry (Q2) | ||
| Dergi ISSN | 1756-8919 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 02-2026 |
| Cilt / Sayı / Sayfa | 18 / 4 / 415–428 | DOI | 10.1080/17568919.2026.2620368 |
| Makale Linki | https://doi.org/10.1080/17568919.2026.2620368 | ||
| UAK Araştırma Alanları |
Organik Kimya
|
||
| Özet |
| AimLung cancer remains a leading cause of cancer-related deaths, largely due to therapy resistance and toxicity. This study develops novel quinazolinone-thiazolidinedione (TZD) hybrids by combining two anticancer pharmacophores to achieve more selective and potent EGFR inhibitors.Materials and methodsA total of 14 quinazolinone-TZD hybrids were synthesized and characterized. Their cytotoxicity was evaluated in A549 lung adenocarcinoma and BEAS-2B normal bronchial cells. EGFR binding was analyzed via molecular docking and MM-GBSA, with 500 ns molecular dynamics simulations supporting the stability of selected complexes. ADME predictions assessed drug-likeness and oral bioavailability.ResultsSeveral compounds showed selective cytotoxicity against A549 cells, with compound 9 (thiophen-2-ylmethyl substituent) emerging as the most active (IC50 = 3.85 μM, SI = 36.0), outperforming … |
| Anahtar Kelimeler |
| 4-dione | cytotoxicity | EGFR | lung cancer | Quinazolin-4(3H)-one | thiazolidine-2 |
| Atıf Sayıları | |
| Web of Science | 4 |
| Scopus | 3 |
| Google Scholar | 4 |
| Dergi Adı | Future Medicinal Chemistry |
| Yayıncı | Taylor and Francis Ltd. |
| Açık Erişim | Hayır |
| ISSN | 1756-8919 |
| E-ISSN | 1756-8927 |
| CiteScore | 4,8 |
| SJR | 0,501 |
| SNIP | 0,575 |